Kelly Shi
Stock Analyst at Jefferies
(2.01)
# 2,951
Out of 4,761 analysts
26
Total ratings
41.67%
Success rate
-4.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelly Shi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TIL Instil Bio | Upgrades: Buy | $11 → $52 | $22.12 | +135.08% | 2 | Jan 7, 2025 | |
| FHTX Foghorn Therapeutics | Maintains: Buy | $18 → $14 | $5.23 | +167.69% | 2 | Dec 16, 2024 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $13 → $19 | $16.63 | +14.25% | 2 | Sep 11, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $174 → $196 | $152.43 | +28.58% | 2 | Aug 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | $21 | $3.77 | +457.03% | 1 | Aug 13, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $37 | $16.38 | +125.89% | 1 | Jun 28, 2024 | |
| PROK ProKidney | Maintains: Buy | $15 → $6 | $1.50 | +300.00% | 2 | Jun 10, 2024 | |
| PTCT PTC Therapeutics | Maintains: Buy | $35 → $46 | $50.69 | -9.25% | 3 | May 20, 2024 | |
| INCY Incyte | Initiates: Buy | $81 | $72.11 | +12.33% | 1 | Feb 23, 2024 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $35 | $27.07 | +29.29% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $2.06 | +1,647.57% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $42.33 | -62.20% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $36.81 | +8.67% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.22 | +221.54% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $3.42 | +133.92% | 1 | Aug 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $0.97 | +2,673.78% | 1 | Mar 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $52 | $16.11 | +222.78% | 1 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $0.87 | +3,003.09% | 1 | Apr 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $2.06 | +1,501.94% | 1 | Mar 8, 2021 |
Instil Bio
Jan 7, 2025
Upgrades: Buy
Price Target: $11 → $52
Current: $22.12
Upside: +135.08%
Foghorn Therapeutics
Dec 16, 2024
Maintains: Buy
Price Target: $18 → $14
Current: $5.23
Upside: +167.69%
Centessa Pharmaceuticals
Sep 11, 2024
Maintains: Buy
Price Target: $13 → $19
Current: $16.63
Upside: +14.25%
Ascendis Pharma
Aug 13, 2024
Maintains: Buy
Price Target: $174 → $196
Current: $152.43
Upside: +28.58%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: $21
Current: $3.77
Upside: +457.03%
Syndax Pharmaceuticals
Jun 28, 2024
Initiates: Buy
Price Target: $37
Current: $16.38
Upside: +125.89%
ProKidney
Jun 10, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.50
Upside: +300.00%
PTC Therapeutics
May 20, 2024
Maintains: Buy
Price Target: $35 → $46
Current: $50.69
Upside: -9.25%
Incyte
Feb 23, 2024
Initiates: Buy
Price Target: $81
Current: $72.11
Upside: +12.33%
ArriVent BioPharma
Feb 20, 2024
Initiates: Buy
Price Target: $35
Current: $27.07
Upside: +29.29%
Feb 5, 2024
Initiates: Buy
Price Target: $36
Current: $2.06
Upside: +1,647.57%
Nov 11, 2022
Initiates: Buy
Price Target: $16
Current: $42.33
Upside: -62.20%
Aug 15, 2022
Initiates: Buy
Price Target: $40
Current: $36.81
Upside: +8.67%
Aug 15, 2022
Initiates: Buy
Price Target: $20
Current: $6.22
Upside: +221.54%
Aug 3, 2022
Initiates: Buy
Price Target: $8
Current: $3.42
Upside: +133.92%
Mar 4, 2022
Initiates: Buy
Price Target: $27
Current: $0.97
Upside: +2,673.78%
Aug 3, 2021
Initiates: Buy
Price Target: $52
Current: $16.11
Upside: +222.78%
Apr 13, 2021
Initiates: Buy
Price Target: $27
Current: $0.87
Upside: +3,003.09%
Mar 8, 2021
Initiates: Buy
Price Target: $33
Current: $2.06
Upside: +1,501.94%